Skip to main content
BD10-Q: Product launch

BDX manages large-scale replacement of Alaris Infusion Systems under FDA Consent Decree.

What happened

The company's U.S. infusion pump business is operating under an FDA Consent Decree, forcing a large-scale replacement and return-to-market for its BD Alaris™ Infusion Systems.

Source

SEC EDGARAug 6, 2026

Quarterly report (Form 10-Q)

BD 10-Q

Filing excerpt

As a result of the CareFusion acquisition, our U.S. infusion pump business is operating under a Consent Decree with the FDA.

sec.gov/Archives/edgar/data/10795/000001079526000035/bdx-20260630.htmRead the full source

Other signals in this filing (11)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Product launch

What this signalsFilings often name leadership changes, deals and spending plans.

Fiscal year end
06/30
Filed
Aug 6, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Details

CIK
10795
Accession number
0000010795-26-000035
Timeframe
Current year
Filing year
2026
Fiscal year
0
Why it matters
Go-to-market support
Signal category
Strategic

Topics and mentions

Regions named

  • U.S.

Extraction

Confidence
High
Relevance
90%
Sentiment
Negative
Detected
Aug 11, 2026
signal_type
sec-10q
signal_subtype
productLaunch

Use this data

Get every 10-Q signal for BD and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at BD this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/d4116f3a-104d-4222-9bdf-a4171b1f378f returns this record as JSON. POST /v1/companies/enrich returns every signal for bd.com.

{
  "signal_id": "d4116f3a-104d-4222-9bdf-a4171b1f378f",
  "signal_type": "sec-10q",
  "signal_subtype": "productLaunch",
  "detected_at": "2026-08-11T08:11:19.804+00:00",
  "company": {
    "name": "BD",
    "domain": "bd.com"
  },
  "data": {
    "detail": "The company's U.S. infusion pump business is operating under an FDA Consent Decree, forcing a large-scale replacement and return-to-market for its BD Alaris™ Infusion Systems. This creates urgent needs for solutions in supply chain logistics, compliance tracking, customer readiness management, and regulatory reporting to mitigate significant financial and legal risks.",
    "metrics": {
      "timeframe": "current_year"
    },
    "summary": "BDX manages large-scale replacement of Alaris Infusion Systems under FDA Consent Decree.",
    "excerpts": "As a result of the CareFusion acquisition, our U.S. infusion pump business is operating under a Consent Decree with the FDA.",
    "relevance": 0.9,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/10795/000001079526000035/bdx-20260630.htm",
    "filing_date": "2026-08-06",
    "filing_year": 2026,
    "fiscal_year": 0,
    "fiscal_year_end": "06/30",
    "sales_relevance": "Go-to-market support",
    "signal_category": "strategic",
    "regions_mentioned": [
      "U.S."
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.